[
  {
    "ts": null,
    "headline": "Unpacking Q3 Earnings: DaVita (NYSE:DVA) In The Context Of Other Outpatient & Specialty Care Stocks",
    "summary": "Let’s dig into the relative performance of DaVita (NYSE:DVA) and its peers as we unravel the now-completed Q3 outpatient & specialty care earnings season.",
    "url": "https://finnhub.io/api/news?id=50619b08ff5e83c7b2d9b733acec0b1b23590ba92ebf11ef0814f8477439b06f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763091073,
      "headline": "Unpacking Q3 Earnings: DaVita (NYSE:DVA) In The Context Of Other Outpatient & Specialty Care Stocks",
      "id": 137478451,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DVA",
      "source": "Yahoo",
      "summary": "Let’s dig into the relative performance of DaVita (NYSE:DVA) and its peers as we unravel the now-completed Q3 outpatient & specialty care earnings season.",
      "url": "https://finnhub.io/api/news?id=50619b08ff5e83c7b2d9b733acec0b1b23590ba92ebf11ef0814f8477439b06f"
    }
  },
  {
    "ts": null,
    "headline": "DaVita's New Kidney Research Unveiling Might Change The Case For Investing In DVA",
    "summary": "Earlier this week, DaVita unveiled six new clinical studies at the American Society of Nephrology Kidney Week 2025 in Houston, covering advancements in dialysis treatments, middle molecule clearance, and initiatives such as GLP-1 receptor agonists for reducing hospitalizations in end-stage kidney disease patients. One standout research effort was developed through DaVita's unique program that partners with independent medical directors, helping ensure new clinical studies are deeply informed...",
    "url": "https://finnhub.io/api/news?id=5155a30bacad370334656c066e073b7e8077b77dcc50dacd0234d0ada92ce89e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763079476,
      "headline": "DaVita's New Kidney Research Unveiling Might Change The Case For Investing In DVA",
      "id": 137477188,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DVA",
      "source": "Yahoo",
      "summary": "Earlier this week, DaVita unveiled six new clinical studies at the American Society of Nephrology Kidney Week 2025 in Houston, covering advancements in dialysis treatments, middle molecule clearance, and initiatives such as GLP-1 receptor agonists for reducing hospitalizations in end-stage kidney disease patients. One standout research effort was developed through DaVita's unique program that partners with independent medical directors, helping ensure new clinical studies are deeply informed...",
      "url": "https://finnhub.io/api/news?id=5155a30bacad370334656c066e073b7e8077b77dcc50dacd0234d0ada92ce89e"
    }
  }
]